Endogenous plasma IgG sets an immunological threshold that dictates the activity of tumordirected therapeutic antibodies. Saturation of cellular antibody receptors by endogenous antibody limits antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Here we show how enzymatic cleavage of IgG using the bacterial enzyme IdeS can be utilized to empty both high and low affinity Fcγ-receptors and clear the entire endogenous antibody pool. Using in vitro models, tumor animal models as well as ex vivo analysis of sera collected during a previous clinical trial with IdeS, we show how clearing of competing plasma antibody levels with IdeS unblocks cellular antibody receptors. We show that therapeutic antibodies against breast cancer (trastuzumab), colon cancer (cetuximab) and lymphomas (rituximab and alemtuzumab) can be potentiated when endogenous IgG is removed.
Introduction
The mechanism of action of therapeutic antibodies against cancerous cells ranges from direct manipulation of endogenous signaling systems, direct target-induced cell death, to the recruitment of the immune system. However, the majority of therapeutic antibodies in clinical use induce complement-dependent cytotoxicity (CDC), antibody-dependent cytotoxicity (ADCC) and/or phagocytosis (ADCP) to kill target cells (1) . CDC is triggered via the complement cascade which is initiated by complement factors binding to the Fc-part of an antigen-bound/aggregated antibody and results in killing of target cells or pathogens. In contrast, ADCC and ADCP are triggered via interaction of the IgG Fc with cell-surface Fc γ-receptors (FcγRs) expressed by, for example, neutrophils, NK cells, monocytes, macrophages, dendritic cells and eosinophils (2, 3) .
While the interaction of a therapeutic antibody with host effector molecules is necessary for Fc-mediated immune recruitment, it is known that high serum concentration of endogenous plasma IgG has a negative impact on many in vitro assays. This suppressive effect has been attributed to the gamma globulin (IgG) fraction and its binding to FcγRs (4) (5) (6) . The high plasma L/mol for CD64/FcγRI, CD32/FcγRII, CD16/FcγRIII, respectively). Functionally, this means that the receptors are impeded by the endogenous IgG (7, 8) .
While all receptors are near saturation with plasma IgG, the high affinity receptor, FcγRI, which can functionally bind monomeric IgG is naturally most impeded. An alleviation of the suppressive effect of endogenous IgG is likely to have an enhancing effect on the cell killing activity on a wide range of immunological cells expressing FcγRI. To this end, aglycosylated antibodies which show abrogated binding to the low-affinity receptors but which have been engineered to engage FcγRI exhibited profound ADCC activity and points to the capacity of FcγRI as an important mediator of effector functions (9) . A further example of potential therapeutic benefit of recruiting FcγRI+ cells is the use of bispecific antibodies capable of crosslinking FcγRI with target cells (10) . It is not fully understood what the main function of the high affinity receptor is in vivo, however, animal experiments with FcγRI knock-outs have shown that at least the murine FcγRI is vital for therapeutic antibody efficacy (11) .
In contrast to the high affinity receptor, there are three human FcγRs that mainly functionally respond to complexed IgG (CD16, CD32a and CD32b) (12) . Their main functions to remove target structures by ADCC and ADCP are also well established in vitro and there is also accumulating evidence for their importance for clinical response to therapeutic antibodies (13) (14) (15) . One strategy that has been employed to overcome the suppressive effects of competing IgG is to engineer the protein or glycosylation component of the therapeutic antibody Fc domain to generate enhanced receptor affinity (16) (17) (18) (19) (20) . For example, the inhibitory effect of serum IgG on ADCC could be alleviated by defucosylation of anti-CD20 and anti-Lewis Y antibodies which enhances the binding to FcγRIIIA (21-23). However, this strategy is highly dependent on the target density and the concentration of the therapeutic antibody. Importantly, low target density renders the therapeutic antibody particularly prone to suppression by plasma IgG (6, 24) . Thus, strategies to directly manipulate the competing plasma IgG are being considered as a way to boost the efficacy and clinical outcome of therapeutic antibody therapy against cancer (25, 26) . It is envisioned that relief of suppression by plasma IgG would stimulate tumour killing activity by all immunological effector cells particularly by uncovering the most impeded and widely expressed receptor, FcγRI.
Adults have on average 10 g/L (6.7-14.5 g/L) intravascular IgG (27), however more than half of the total amount of IgG is present in the extravascular compartment (28). This high concentration and in vivo distribution results in a massive buffering capacity when trying to reduce circulating IgG levels by means of immunoadsorption or plasmaexchange. Thus, reducing IgG levels using these procedures takes several rounds of treatment allowing intra/extravascular equilibrium in IgG to establish between each round (29,30). These procedures can take several weeks and has to compete against the constant production of new IgG. Hence, accomplishing a rapid and dramatic change in IgG levels in human subjects has not been possible until now.
Recently, a clinical phase I study with IdeS demonstrated that upon injection of IdeS to human subjects the IgG levels dropped within minutes and IgG didn't start to reappear until several days later (31). IdeS cleaves IgG below the hinge region in a two-step reaction. It first cleaves one of the heavy chains generating a single cleaved IgG molecule (scIgG) which introduce a conformational change in the IgG. Secondly, the remaining heavy chain is also cleaved ultimately leading to the release of a F(ab′) 2 fragment and a dimeric Fc fragment (31).
Here we show how IdeS can create a therapeutic window in which both high and low affinity FcγRs may be empty and can be armed with therapeutic antibodies thereby equipping them to be dedicated tumor seeking immune cells.
Material and Methods

Solid phase assays
Recombinant human CD64, CD16a, CD32a or CD32b/c (all R&D System) were coated in MaxiSorp plates at 2 µg/mL in PBS. Plates were blocked with 2% bovine serum albumin (BSA) in PBS and incubated with human IgG (IVIg, Octagam) at 1-2 µg/mL, either before or after IdeS treatment at indicated concentrations (37ᵒC, 1 hour). PBS with 0.1% BSA was used for all dilutions and PBS with 0.05% Tween-20 (PBS-T) was used for all wash steps. Binding of IgG was detected using either a biotin-conjugated anti-Fab (109-066-097, Jackson ImmunoResearch) or anti-Fc (109-066-098, Jackson ImmunoResearch) antibody followed by horseradish peroxidase (HRP) conjugated streptavidin (SA-HRP, Pierce). Signals were developed using 3,3´,5,5´-tetramethylbenzidine substrate (TMB one component HRP, BioFX Laboratories), stopped using 0.5 M H 2 SO 4 and read at 450 nm. Blank was withdrawn from all samples and maximum binding using IVIg without IdeS was assigned 100%.
Human IgG concentration determination in mouse serum was measured using a Meso Scale Diagnostic (MSD) based assay developed at Hansa Medical AB. Briefly, a goat anti-human Fab fragment specific antibody was coated in MSD micro titre plates overnight. Plates were washed (PBS-T) and blocked in 2% BSA in PBS-T. A human IgG calibrator was applied as well as diluted serum samples and controls. Plates were washed and a biotinylated goat-anti-human Fc-specific antibody was applied together with streptavidin-sulfo (R32AD-1, MSD). Plates were washed, Read buffer T (R92TC-2, MSD) was added to plates and signals acquired using a MSD Sector Imager.
SDS-PAGE and immunoblotting
IdeS-cleaved IgG generated for the solid phase assays was separated under non-reducing conditions on a 4-20% Mini-PROTEAN TGX Stain-Free gel (BioRad) in Tris-Glycine-SDS buffer. The gel was transferred to a 0.45 µm Nitrocellulose membrane and blocked in 5% non-fat milk (NFM) prior to incubation with biotin-conjugated anti-Fc in 1% NFM/PBS-T. The membrane was washed, incubated with SA-HRP and developed with LumiLight ECL solution (Amersham). Signals were acquired using a ChemiDoc MP system (BioRad). The breast carcinoma cell line SK-BR-3 (ACC736) and the colon adenocarcinoma cell line HT-29 (ACC299) were obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and maintained in McCoy's 5A with 10% fetal bovine serum (FBS) and penicillin/streptomycin (PEST). The B-cell lymphoma cell line Nu-DUL-1 (ACC579) and the Burkitt lymphoma cell line Daudi (ACC78), also from DSMZ, were maintained in RPMI1640 with 10% FBS and PEST (R10). The acute monocytic leukemia cell line THP-1, a kind gift from Dr. Maria Allhorn, Lund University, Sweden, was maintained in R10. No authentication was done by the authors for any of the cell lines. PBMCs were prepared by density gradient separation (FicollPaquePLUS) of blood obtained from healthy human volunteers.
Cells and cell lines
Binding of IgG to cells
THP-1 cells were incubated with different concentrations of either polyclonal IgG (IVIg) or with a monoclonal IgG1, adalimumab (Humira, AbbVie) and stained using a biotin-conjugated antiFab or anti-Fc specific antibody followed by allophycocyanin-conjugated streptavidin (SA-APC). 
Complement dependent cytotoxicity and proliferation
Daudi cells were harvested and 50,000 cells/mL were seeded in a 96-well plate. Wells without cells were filled with R10. Rituximab was diluted to 400 µg/mL in R10 and further 10× dilutions were prepared. Twenty-five µL of the rituximab dilutions were added and the plate was incubated at 37°C for 30 min. Baby rabbit complement (Cederlane) and heat-inactivated complement (56°C, 30 min) was diluted 5× in R10 and 25 µL was added to wells. The plate was incubated at 37°C in the CO 2 Laboratories) was added to all wells and the plate was incubated for at least one hour at 37°C.
The plate was read at 450 nm in an ELISA plate reader. Survival rates were calculated using the following formula: Survival rate (%) = A sample -A blank / A neg.ctrl -A blank × 100. Negative control is cells without antibody treatment (maximum survival) and blank is wells without cells.
Significance was calculated using GraphPad PRISM, One-way ANOVA, Sidak's multiple comparisons test, P < 0.0001 at 0.1 µg/mL rituximab.
For Daudi cell proliferation in the precense of test substances (IdeS, puromycin, rituximab and IVIg), the CCK-8 kit was used with the same set up as for CDC, but seeding 15,000 cells/well and incubating for 48 hours prior to addition of CCK-8. Test substances were used at 100 µg/mL and in 10× dilutions to 1 ng/mL. No complement was added to the proliferation experiments.
Xenograft model in SCID mice
Six week old female severe combined immunodeficient mice (CB17-SCID, Janvier Labs, France) were allowed to acclimatize for at least one week. Mice were inoculated subcutaneously (s. 
Statistical analysis
GraphPad PRISM software was used for all statistical analysis and the method used is specified for each experimental type individually (method sections and figure legends). 
Results
IdeS has the capacity to unblock cellular FcγRs
It has been shown that IdeS can cleave both free IgG, antigen-bound IgG as well as IgG constituting part of the IgG-type of B-cell receptor (32), however, whether IdeS can also cleave IgG when bound by FcγRs has not been established. In a set of experiments, we assessed the effect of IdeS on IgG-binding to different recombinant FcγRs, i.e. CD16a, CD32a and CD64 (Fig. 1 ). CD32b was also tested but we did not achieve signals above background using that receptor. Normal human IgG (IVIg) was treated with different concentrations of IdeS (0.03-30 µg/mL) prior to incubation with immobilized FcγRs. The results demonstrate that IgG cleaved by IdeS does not bind the low affinity FcγRs, CD16a or CD32a, even when low concentrations of IdeS were used and that IdeS completely prevented binding to the high affinity FcγRI receptor CD64 when used at higher concentrations above 3 µg/mL (Fig. 1a) . As there was still signal from the high affinity receptor at IdeS concentrations below 3 µg/mL we investigated the composition of the IgG and IgG-fragments present during the binding. IgG was cleaved with different concentrations of IdeS (30 pg/mL to 30 µg/mL), the CD64 interaction assay was repeated and samples of the IdeS-treated IgG were also subjected to SDS-PAGE and immunoblot in order to address the digestion status of the IgG added to the plate (Fig. 1b) . The results show that at high concentrations of IdeS (3 and 30 µg/mL) the IgG was completely cleaved into Fc and F(ab′) 2 and there was no binding to CD64. However, at low concentrations (between 0.003 and 0.3 µg/mL) there was a fraction of scIgG present in the samples which interacted with CD64, although potentially with lower affinity. At very low concentrations of IdeS (30 and 300 pg/mL) un-cleaved IgG was present and responsible for the binding to CD64. Thus, it could be concluded that the high affinity receptor but not the low affinity receptors can bind scIgG. (Fig. 2b, green line) .
When IdeS was added to the plasma-incubated PBMCs, there was a clear drop in MFI during the first two hours after IdeS addition (Fig. 2b, red line) . Incubating PBMCs with plasma pre-treated with IdeS resulted in a small additional drop in MFI over time indicating that after standard density gradient PBMC purification there is still a small amount of IgG in the FcγRs, and this is gradually removed by IdeS (Fig. 2b , blue line). Two hours post IdeS treatment there was no difference between cells given pre-cleaved plasma or plasma followed by IdeS treatment and hence, IdeS treatment resulted in emptying of FcγRs also on primary cells. Plasma used in this experiment was separated by SDS-PAGE to visualize the composition of IgG and IgG-fragments at each time point (Supplementary Fig. S1 ). An inhibitor was added to the samples immideately to stop additional IdeS activity and the results clealy shows that IdeS efficacy on non-bound IgG is much faster than on FcγR-bound IgG.
One possible mechanism of IdeS-mediated receptor clearence is that IdeS cleavage occurs most readily once IgG is detached from the receptors thereby reducing the concentration of liganded receptor as the system shifts to maintain equilibrium, slowly shifting the equilibrium concentrations until the FcγRs are unliganded. To test this explanation for the observed slow decrease in cell-bound IgG, IdeS treated cells were compared to cells allowed to passively equilibrate against buffer only. THP-1 cells with bound IgG were washed repetedly to remove non-bound IgG prior to addition of either PBS or IdeS and aliquots were removed and analysed by flow-cytometry at different time points (Fig. 2c) . The results showed that during the first hour (Fig. 3c) . However, IdeS-treated IgG had no blocking effect on the effector activity and rescued the therapeutic effect of alemtuzumab. The same suppressive pattern with non-treated polyclonal IgG blocking ADCP was seen with all tested antibodies, exemplified by cetuximab on the colon adenocarcinoma cell line HT29 and trastuzumab on the breast cancer cell line SK-BR-3 ( Fig.3d and e) .
IdeS potentiates therapeutic antibody treatment in vivo
The relevance of occupied FcγR was evaluated in vivo using rituximab as a therapeutic antibody and Daudi as target cells. SCID mice lack plasma IgG which is an advantage since IdeS does not effectively cleave murine IgG and instead mice were supplemented with human polyclonal IgG (IVIg). Flow cytometry analysis showed that rituximab binds well to target cells (Fig. 4a) and that rituximab has only a limited direct effect on the survival of Daudi in vitro (Fig. 4b) . We further addressed the capacity of rituximab to fix complement and induce CDC in Daudi cells and rituximab was shown to significantly induce CDC at doses above 0.1 μg/mL (Fig. 4c) 
on Daudi cell proliferation was also addressed in a 48 hour proliferation experiment in the presence of 0.1-100 µg/mL IdeS and there was no impact on Daudi cell proliferation in the presence of IdeS (Supplementary Fig. S2 ). An in vivo model was developed to be able to evaluate the effect of human polyclonal IgG (IVIg) on therapeutic antibody efficacy. Several cell lines expressing CD20 on the surface was monitored for tumor take in SCID mice and Daudi cells were Mice were further dosed with IdeS or PBS once daily for three days and then given rituximab or PBS once weekly starting on day 14 after tumor inoculation. There was no significant difference between the IVIg and control groups ( IgG competes with the therapeutic antibody for effector cell binding. Interestingly, IdeS treatment after IVIg dosing significantly (p < 0.0001) rescued the therapeutic effect of rituximab (Fig 4.e) .
IVIg did not completely block the therapeutic effect of rituximab and this is most likely because not only FcγR-mediated activities, but also CDC and possibly direct effects, contributes to the therapeutic activity of rituximab in this model as suggested by the in vitro experiments in Fig. 4b and c and by others (34) .
In order to address if human IgG was present on the potential effector cells in SCID mice, we injected mice with PBS, IVIg or IVIg followed by IdeS and prepared splenocytes. Cells were stained for the presence of human IgG and evaluated using flow cytometry. Mice given IVIg had a strong IgG-specific signal from the lymphocyte population whereas mice given IVIg followed by IdeS did not differ from the PBS control (Fig. 4f ). Cells were also double stained for the presence of human IgG and either CD335, Ly6G (Gr-1) or CD11b and evaluated using flow cytometry. Human of IdeS in chronic kidney disease patients has been conducted at Uppsala University Hospital, Sweden with Hansa Medical AB as sponsor (Eudract No 2013-005417-13). Pre-dose sera collected from subjects were screened by flow cytometry to address if they had natural plasma antibodies against Daudi and THP-1 cells. As expected many of the subjects were positive as they have anti-HLA antibodies against many potential donors (sensitized), however, two subjects were found to be negative. Sera collected pre-dose and at different time-points post dosing of 0.25 mg/kg body weight of IdeS were separated by SDS-PAGE to monitor IgG and the different IdeS-generated IgG fragments (scIgG, F(ab') 2 and Fc) and a representative gel is shown (Fig. 5a ). Sera from two subjects were tested ex vivo for blocking capacity in a rituximab/Daudi experiment. The pre-dose sera from both individuals could significantly (p < 0.0001) inhibit rituximab mediated ADCP of target cells and the sera collected 24 hours post IdeS dosing did not block ADCP (Fig. 5b) . These results suggest that a single dose of IdeS can reduce the IgG levels in humans to levels where the 
